Biocorp Production

Biocorp Production Liabilities

Delisted

The The Liabilities of Biocorp Production (ALCOR.PA) as of Oct 27, 2026 is 10.12 M EUR. In the previous year, The Liabilities was 7.53 M EUR — a change of 34.41% (higher).

Liabilities

10.12 MEUR

YoY

34.41%

Last updated:

In 2022, Biocorp Production's total liabilities amounted to 10.12 M EUR, a 34.41% difference from the 7.53 M EUR total liabilities in the previous year.

The Biocorp Production Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2015
4.93 M EUR
Jan 1, 2016
4.52 M EUR
Jan 1, 2017
6.53 M EUR
Jan 1, 2018
6.90 M EUR
Jan 1, 2019
6.74 M EUR
Jan 1, 2020
8.87 M EUR
Jan 1, 2021
7.53 M EUR
Jan 1, 2022
10.12 M EUR
The Biocorp Production Liabilities history
YEARLiabilitiesYoY
10.12 MEUR+34.41%
7.53 MEUR-15.09%
8.87 MEUR+31.59%
6.74 MEUR-2.32%
6.90 MEUR+5.72%
6.53 MEUR+44.56%
4.52 MEUR-8.48%
4.93 MEUR-0.31%
4.95 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Biocorp Production's Liabilities

Biocorp Production's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Biocorp Production's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Biocorp Production's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Biocorp Production's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Biocorp Production’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Biocorp Production stock

The Liabilities of Biocorp Production is 10.12 M EUR in 2022.

The Liabilities of Biocorp Production changed from 7.53 M EUR to 10.12 M EUR, representing a 34.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Biocorp Production historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocorp Production

All Key Metrics — Biocorp Production